Mark J. Smyth
Mark J. Smyth
Verified email at
Cited by
Cited by
Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion
RD Schreiber, LJ Old, MJ Smyth
Science 331 (6024), 1565-1570, 2011
Natural innate and adaptive immunity to cancer
MD Vesely, MH Kershaw, RD Schreiber, MJ Smyth
Annual review of immunology 29, 235-271, 2011
Activation of the NLRP3 inflammasome in dendritic cells induces IL-1β–dependent adaptive immunity against tumors
F Ghiringhelli, L Apetoh, A Tesniere, L Aymeric, Y Ma, C Ortiz, ...
Nature medicine 15 (10), 1170-1178, 2009
Immune surveillance of tumors
JB Swann, MJ Smyth
The Journal of clinical investigation 117 (5), 1137-1146, 2007
New insights into cancer immunoediting and its three component phases—elimination, equilibrium and escape
D Mittal, MM Gubin, RD Schreiber, MJ Smyth
Current opinion in immunology 27, 16-25, 2014
Adaptive immunity maintains occult cancer in an equilibrium state
CM Koebel, W Vermi, JB Swann, N Zerafa, SJ Rodig, LJ Old, MJ Smyth, ...
Nature 450 (7171), 903-907, 2007
Functional significance of the perforin/granzyme cell death pathway
JA Trapani, MJ Smyth
Nature Reviews Immunology 2 (10), 735-747, 2002
NKT cells: what's in a name?
DI Godfrey, HR MacDonald, M Kronenberg, MJ Smyth, LV Kaer
Nature Reviews Immunology 4 (3), 231-237, 2004
Classifying cancers based on T-cell infiltration and PD-L1
MWL Teng, SF Ngiow, A Ribas, MJ Smyth
Cancer research 75 (11), 2139-2145, 2015
Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting
H Matsushita, MD Vesely, DC Koboldt, CG Rickert, R Uppaluri, VJ Magrini, ...
Nature 482 (7385), 400-404, 2012
Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial
S Loi, S Michiels, R Salgado, N Sirtaine, V Jose, D Fumagalli, ...
Annals of oncology 25 (8), 1544-1550, 2014
Cancer immunoediting and resistance to T cell-based immunotherapy
JS O’Donnell, MWL Teng, MJ Smyth
Nature reviews Clinical oncology 16 (3), 151-167, 2019
NKT cells: facts, functions and fallacies
DI Godfrey, KJL Hammond, LD Poulton, MJ Smyth, AG Baxter
Immunology today 21 (11), 573-583, 2000
Differential tumor surveillance by natural killer (NK) and NKT cells
MJ Smyth, KYT Thia, SEA Street, E Cretney, JA Trapani, M Taniguchi, ...
The Journal of experimental medicine 191 (4), 661-668, 2000
Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity
MJ Smyth, GP Dunn, RD Schreiber
Advances in immunology 90, 1-50, 2006
Type I interferons in anticancer immunity
L Zitvogel, L Galluzzi, O Kepp, MJ Smyth, G Kroemer
Nature Reviews Immunology 15 (7), 405-414, 2015
A fresh look at tumor immunosurveillance and immunotherapy
MJ Smyth, DI Godfrey, JA Trapani
Nature immunology 2 (4), 293-299, 2001
Translational biology of osteosarcoma
M Kansara, MW Teng, MJ Smyth, DM Thomas
Nature Reviews Cancer 14 (11), 722-735, 2014
New aspects of natural-killer-cell surveillance and therapy of cancer
MJ Smyth, Y Hayakawa, K Takeda, H Yagita
Nature Reviews Cancer 2 (11), 850-861, 2002
Targeting natural killer cells in cancer immunotherapy
C Guillerey, ND Huntington, MJ Smyth
Nature immunology 17 (9), 1025-1036, 2016
The system can't perform the operation now. Try again later.
Articles 1–20